MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Feb 9, 2010 - ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the Oncologic Drugs Advisory Committee (ODAC) public advisory meeting scheduled for 10 February 2010 has been suspended due to extreme weather conditions in Washington D.C.
SEATTLE--(BUSINESS WIRE)--Feb 9, 2010 - Targeted Genetics Corporation (Pink Sheets:TGEN) (the “Company”) today announced that it has completed the technology transfer portion of the September 2009 asset sale transaction executed between the Company and Genzyme Corporation (“Genzyme”) and has received the full $7.0 million provided for in the asset purchase agreement.
RADNOR, Pa.--(BUSINESS WIRE)--Feb 9, 2010 - PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a presentation by President & C.E.O., Nicholas Landekic at the 2010 BIO CEO & Investor Conference. A replay of the webcast is available at http://www.veracast.com/webcasts/bio/ceoinvestor2010/27101233.cfm.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Feb 9, 2010 Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended December 31, 2009, on Wednesday, February 17, 2010 at approximately 8:00 am Eastern Time (ET). The release will be followed by a live conference call, which will begin at approximately 10:00 am Eastern Time (ET) on Wednesday, February 17, 2010.
CHATTANOOGA, Tenn.--(BUSINESS WIRE)--Feb 9, 2010 - Chattem, Inc. (NASDAQ: CHTT) announced that, pursuant to the terms of the indentures (the “Indentures”) governing its 2.00% convertible senior notes due 2013 and 1.625% convertible senior notes due 2014 (collectively, the “Notes”), a Fundamental Change (as such term is defined in the respective Indentures) occurred on February 9, 2010 (the “Fundamental Change Effective Date”) as a result of the successful completion of the tender offer, commenced by River Acquisition Corp., a Tennessee corporation and an indirect wholly-owned subsidiary of sanofi-aventis, a French société anonyme, on January 11, 2010, for all outstanding shares of common stock of Chattem for $93.50 per share, net to the seller in cash, without interest and less any required withholding taxes pursuant to the Agreement and Plan of Merger, dated December 20, 2009, among Chattem, sanofi-aventis and River Acquisition Corp.
CHENGDU, China, Feb. 9 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and Western Pharmaceuticals based in Chengdu, China, today announced that it expects operational benefits from the recently published Guide to Reform of Pricing Mechanism of Medicine and Medical Services by the Chinese government.
SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (NASDAQ:RDEA) today announced that Felix J. Baker, Ph.D., has been appointed to the Company's Board of Directors. Dr. Baker is a managing partner of Baker Bros. Advisors, LLC, the manager and advisor to the funds of Baker Brothers Investments, Ardea's largest shareholder.
SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Pacific Biomarkers, Inc. (OTC Bulletin Board: PBME), which provides specialty reference biomarker services to support pharmaceutical and laboratory diagnostic manufacturers in the conduct of human clinical research, today announced that it has scheduled an investor conference call for 11:15 a.m. EST (8:15 a.m. PST) on Friday, February 12, 2010 to review the Company's operating results for the second quarter and first half of FY2010. The Company intends to report its operating results prior to the conference call.
SAN FRANCISCO, Feb. 9 /PRNewswire/ -- endpoint Clinical (www.endpointclinical.com), a leader in Integrated Voice Response (IVR)/Integrated Web Response (IWR) systems, announced today that PULSE, a fully configurable platform that allows users to design and deploy clinical trial Integrated Response Technology (IRT) systems, saves 40 percent on the development time of clinical trials. This time and cost savings stems from PULSE's ability to provide pre-validated programs so developers do not have to spend valuable time re-configuring studies. For some studies, endpoint will deliver a validated study program in just four weeks rather than eight weeks.
SOUTHFIELD, Mich., Feb. 9 /PRNewswire-FirstCall/ -- TechTeam Global, Inc., (NASDAQ:TEAM) , a worldwide provider of information technology outsourcing and business process outsourcing services, announced today that it has named Guido Roumans as director of global life sciences services. Roumans will be responsible for service delivery, relationship management and ongoing capability enhancement in support of TechTeam's life sciences customers
LOS ANGELES, Feb. 9 /PRNewswire/ -- THE Aesthetic Show, the leading multidisciplinary educational forum for the medical aesthetic market, today announced the debut of THE Aesthetic Academy, the first regionally-based event series dedicated to providing the most comprehensive practice building course in medical aesthetics.
DAYTONA, Fla., Feb. 9 /PRNewswire/ -- WHAT: The DRIVE4COPD Race Team of Jim Belushi, Bruce Jenner, Patty Loveless and Michael Strahan are beginning a cross-country race to find people who may be at risk for chronic obstructive pulmonary disease (COPD) and don't know it. The goal: to screen at least 1 million people this year on DRIVE4COPD.COM.
IRVINE, Calif., Feb. 9 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA) today announced financial guidance for the full year 2010. The Company expects net revenue will be approximately $147 to $165 million. In addition, ISTA's management anticipates reporting its first profitable year in 2010, with earnings per share for the full year expected to be at least $0.02, excluding any mark-to-market adjustments relating to warrants.
WILMINGTON, Del., Feb. 9 /PRNewswire/ -- The rapid increase of cost in China has brought some shadow to the CRO and CMO businesses there. However, DS Chemphy, Inc., a USA-based contract research and manufacturing organization that focuses on fine and pharmaceutical chemicals, continues investing in its businesses. "Our competitive advantages are not only low costs," said Dr. Aaron Shen, CEO of the company.
DEERFIELD, Ill., Feb. 9 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.
DUSSELDORF, Germany, February 9/PRNewswire-FirstCall/ --Chief Executive Officer Dr. Axel Herberg (51) is not seeking reappointment and will leave the Management Board when his contract expires in June. The Supervisory Board has received this decision with regret and in its meeting today appointed as Herberg's successor from June the Management Board member of many years' standing, Uwe Rohrhoff (47).
ROCHESTER, N.Y., Feb. 9 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (NASDAQ:VSCP) , a provider of quantitative imaging for clinical trials, today announced revenues for the fourth quarter ended December 31, 2009 exceeded $2.9 million, representing a 50% increase over the same period in 2008. Full year 2009 revenues were approximately $10.4 million compared to $7.1 million for 2008. Cash flow generated during 2009 was $1.2 million compared to a cash flow usage of over ($800,000) in 2008.
Pact will broaden SIRO's reach in Asian Clinical trials sector
MUMBAI, India, Feb. 9 /PRNewswire/ -- SIRO Clinpharm, a Contract Research Organization (CRO) with a presence in India, Western and Central Eastern Europe, and the United States today announced its alliance with DreamCIS Inc., a leading CRO based in Seoul, South Korea.
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Feb 9, 2010 - Advaxis, Inc., the live, attenuated Listeria monocytogenes immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
LAKE FOREST, Ill., Feb. 9 /PRNewswire-FirstCall/ -- Akorn, Inc. (NASDAQ: AKRX) will host a conference call on Tuesday, March 16, 2010, to discuss fourth quarter and year-end 2009 results followed by a Q&A session. The company will release earnings the same day before the market opens.
|
